Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259714 | 1.00 | HDAC1 (0.62) | HDAC1NAMPTGSK3BNPC1RAB9A | |
| SCHEMBL2136124 | 0.84 | HDAC1 (0.64) | HDAC1HDAC3HDAC2 | |
| SCHEMBL2136117 | 0.84 | HDAC1 (0.64) | HDAC1HDAC3HDAC2 | |
| SCHEMBL4269528 | 0.82 | HDAC1 (0.82) | HDAC1NAMPTGSK3BHDAC3HDAC2 | |
| SCHEMBL4269526 | 0.82 | HDAC1 (0.82) | HDAC1NAMPTGSK3BHDAC3HDAC2 | |
| SCHEMBL2134266 | 0.82 | RAB9A (0.58) | HDAC1GSK3BNPC1RAB9AHDAC3 | |
| SCHEMBL2134277 | 0.82 | RAB9A (0.58) | HDAC1GSK3BNPC1RAB9AHDAC3 | |
| SCHEMBL7938250 | 0.80 | RAB9A (0.56) | HDAC1GSK3BNPC1RAB9AHDAC3 | |
| SCHEMBL4260735 | 0.80 | SMN1; SMN2 (0.65) | HDAC1NAMPTNPC1RAB9AHDAC3 | |
| SCHEMBL4260737 | 0.80 | SMN1; SMN2 (0.65) | HDAC1NAMPTNPC1RAB9AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | HDAC1 1/4885NAMPT 214/4885GSK3B 348/4885 |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | HDAC1, AADAC, HDAC11 | HDAC1 1/4885NAMPT 351/4885GSK3B 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.